INT224441

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.33
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 4
Disease Relevance 1.61
Pain Relevance 0.27

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (Pdgfb) cytoplasm (Pdgfb)
Anatomy Link Frequency
fat 1
Pdgfb (Mus musculus)
Pain Link Frequency Relevance Heat
metalloproteinase 10 98.46 Very High Very High Very High
Inflammation 49 92.16 High High
Arthritis 29 73.52 Quite High
cva 6 71.12 Quite High
Potency 1 29.60 Quite Low
Inflammatory response 33 27.76 Quite Low
fibrosis 12 10.96 Low Low
cytokine 17 5.00 Very Low Very Low Very Low
imagery 10 5.00 Very Low Very Low Very Low
rheumatoid arthritis 8 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Adhesions 1 98.66 Very High Very High Very High
Arthritis 42 93.36 High High
Targeted Disruption 48 93.12 High High
INFLAMMATION 71 92.16 High High
Apoptosis 102 73.36 Quite High
Hemorrhage 9 71.12 Quite High
Diabetes Mellitus 4 68.12 Quite High
Injury 7 67.64 Quite High
Metastasis 2 66.64 Quite High
Cancer 16 64.40 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Among more than 50 known angiogenic factors (including matrix metalloproteinases, adhesion molecules, enzymes, and growth factors), we found that expression levels of PDGF-B, PDGF receptor ?
Negative_regulation (levels) of PDGF-B associated with metalloproteinase and adhesions
1) Confidence 0.33 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2246237 Disease Relevance 1.22 Pain Relevance 0.24
The VEGF inhibitor, bFGF inhibitor and PDGF inhibitor each reduced HUVEC proliferation significantly, whereas either a combination of the 3 inhibitors together or wortmannin alone abolished HUVEC proliferation.
Negative_regulation (inhibitor) of PDGF
2) Confidence 0.09 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2981551 Disease Relevance 0.26 Pain Relevance 0.04
The cultured HUVECs were treated with or without 100 IU/ml EPO for 48 hours, and then exposed for 3 hours to (a) 0.25 mg/ml bevacizumab, (b) 100 nM of PD173074; an inhibitor of bFGF (Calbiochem, San Diego, CA), (c) 20 ┬ÁM of tyrphostin AG 1296; a selective inhibitor of PDGF (sigma), (d) a combination of bevacizumab, PD173074 and tyrphostin, and to (e) 100 nM wortmannin; a phosphatidylinositol 3-kinaz (PI 3-K) inhibitor (sigma).
Negative_regulation (inhibitor) of PDGF
3) Confidence 0.09 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2981551 Disease Relevance 0 Pain Relevance 0
Furthermore, EPO normalized in vitro HUVEC proliferation in the presence of a single growth factor inhibitor such as bevacizumab (VEGF inhibitor), PD173074 (bFGF inhibitor) or tyrphostin (PDGF inhibitor), strengthening our claim that the use of one growth factor for fat tissue vascularization might not be adequate.
Negative_regulation (inhibitor) of PDGF in fat
4) Confidence 0.09 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2981551 Disease Relevance 0.14 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox